Shire says that by moving to a world-class IS service partner it expects to improve
the cost-effectiveness, efficiency and scalability of its IS Operations to support
the continuation of its strong record of expansion, acquisition and new product
innovation.

John Cogan, Vice-President, IS Operations at Shire, said: ‘Working with Capgemini
will strengthen our ability to increase the scope and scale of our activities,
and do so with the agility and cost-effectiveness that the fast-moving world of
specialty biopharmaceuticals requires.’

Shire says that key factors in its decision to appoint Capgemini included proven
ability to support multinational companies in high-technology businesses especially
pharmaceuticals, its collaborative and practical approach, and its Rightshore®
strategy using Capgemini centres around the world to give Shire users the right
balance of service, quality and cost.

Jerry Clark, Business Development Director at Capgemini, said: ‘We are naturally
delighted to have succeeded in winning this important global contract and we
look forward to working with Shire to deliver the quality of service and benefits
that Shire requires.’

Capgemini will take over responsibilities in December 2007 in the key areas
of IS infrastructure support, IS and data centre operations, and user support,
with a new multi-lingual service desk to support more than 3,000 Shire users worldwide.

Jon Scott, Senior Vice President, Shared Business Services for Shire said: ‘It
was evident during the bid process that Shire and Capgemini are a great cultural
fit. We share the same commitment to dynamism and efficiency, and the same can-do
outlook. We look forward to a long and healthy relationship.’

-ENDS-


SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company
that focuses on meeting the needs of the specialist physician. Shire focuses
its business on attention deficit and hyperactivity disorder (ADHD), human genetic
therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently
flexible to allow Shire to target new therapeutic areas to the extent opportunities
arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts
are focused on products in niche markets with strong intellectual property protection
either in the US or Europe. Shire believes that a carefully selected portfolio
of products with strategically aligned and relatively small-scale sales forces
will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.


About Capgemini

Capgemini, one of the world’s foremost providers of Consulting, Technology and
Outsourcing services, enables its clients to transform and perform through technologies.
Capgemini provides its clients with insights and capabilities that boost their
freedom to achieve superior results through a unique way of working, which it
calls the Collaborative Business Experience. Capgemini reported 2006 global revenues
of EUR 7.7 billion and employs more than 80,000 people worldwide.

More information is available at www.capgemini.com.